KKR and Impilo completed the acquisition of Immedica Pharma.

KKR, a global investment firm, and Impilo, a Nordic healthcare investment firm, completed the acquisition of Immedica Pharma, a pharmaceutical company. Financial terms were not disclosed. “This collaboration with KKR and Impilo marks an exciting step forward in our mission to deliver innovative treatments to more patients with rare diseases. With their support, we are well-positioned to enhance our growth and continue addressing critical unmet medical needs across the globe,” Anders Edvell, Immedica CEO.